Zurcher Kantonalbank (Zurich Cantonalbank) Crispr Therapeutics Ag Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $39 Billion
- Q2 2025
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 24,129 shares of CRSP stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,129
Previous 23,093
4.49%
Holding current value
$1.63 Million
Previous $785,000
49.43%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding CRSP
# of Institutions
532Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$690 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$379 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$249 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$222 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$193 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.28B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....